Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Kadokura, Makoto ^a   Maekawa, Shinya ^a   Sueki, Ryota ^a   Miura, Mika ^a   Komase, Kazuki ^a   Shindo, Hiroko ^a   Amemiya, Fumitake ^a   Uetake, Tomoyoshi ^a   Inoue, Taisuke ^a   Sakamoto, Minoru ^a   Nakagawa, Mina ^b   Sakamoto, Naoya ^b   Watanabe, Mamoru ^b   Enomoto, Nobuyuki ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON ALPHA2B; PROTEIN E2; PROTEIN P7; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHYLOGENY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE; CLASSIFICATION; DRUG EFFECT; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOGENICITY;

HEPATITIS C VIRUS;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OPEN READING FRAMES; PHYLOGENY; RIBAVIRIN; VIRAL PROTEINS; YOUNG ADULT;

EID: 80052830283     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024514     Document Type: Article

References (26)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB, (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, et al. (1989) Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321: 1506-1510.
3. Haydon GH, Jarvis LM, Blair CS, Simmonds P, Harrison DJ, et al. (1998) Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut 42: 570-575.
4. Simmonds P, (1997) Clinical relevance of hepatitis C virus genotypes. Gut 40: 291-293.
5. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
7. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
8. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
9. Rauch A, Kutalik Z, Descombes P, Cai T, di Iulio J, et al. (2010) Genetic variation in IL28B Is Associated with Chronic Hepatitis C and Treatment Failure- A Genome-Wide Association Study. Gastroenterology.
10. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, et al. (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77-81.
11. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, et al. (2008) Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48: 38-47.
12. Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, et al. (2005) Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. J Gastroenterol Hepatol 20: 1401-1409.
13. Chayama K, Suzuki F, Tsubota A, Kobayashi M, Arase Y, et al. (2000) Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy. Hepatology 32: 1138-1144.
14. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, et al. (2005) Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48: 372-380.
15. Duverlie G, Khorsi H, Castelain S, Jaillon O, Izopet J, et al. (1998) Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 79 (Pt 6): 1373-1381.
16. Hofgartner WT, Polyak SJ, Sullivan DG, Carithers RL Jr, Gretch DR, (1997) Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol 53: 118-126.
17. Zeuzem S, Lee JH, Roth WK, (1997) Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 25: 740-744.
18. Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, et al. (2010) Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS One 5: e9032.
19. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, et al. (2007) Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 81: 8211-8224.
20. Kobayashi M, Watanabe K, Ishigami M, Murase K, Ito H, et al. (2002) Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon. Am J Gastroenterol 97: 988-998.
21. Murakami T, Enomoto N, Kurosaki M, Izumi N, Marumo F, et al. (1999) Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 30: 1045-1053.
22. Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, et al. (2011) Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy. Hepatol Int In Press.
23. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, et al. (2009) Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 2a High Viral Load and Virological Response to Interferon-Ribavirin Combination Therapy. Intervirology 52: 301-309.
24. Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, et al. (2009) Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy. J Med Virol 81: 459-466.
25. Gale M Jr, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, et al. (1998) Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 18: 5208-5218.
26. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, et al. (2010) Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol.